AM-Pharma B.V.

Please note: The information displayed on this page might be outdated.
AM-Pharma B.V.: Treating sepsis associated acute kidney injury (SA-AKI) w proprietary recombinant alkaline phosphatase (recAP). Results from Ph 2 in 300+ pts demonstrated improvement of 40%+ OS in recAP group. Initiated Ph 3 in Q4 2020; TL safety & futility analysis on first 400 pts exp YE2021. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023. Raised $52m (Mar 2020), increasing total fundraising to $176m. Investors incl Cowen Healthcare, LSP, Andera, Forbion, Ysios, Kurma Partners, ID Invest , BB Pureos Bioventures & Gilde
Based in...
Clinical Stage
Phase III
Disease Space
Anti-inflammatory, Autoimmune, Metabolic Disorders
Biotechnology, Pharmaceuticals
Stadsplateau 6

Company Participants at 2020 Wall Street "On Tap"

Erik van den Berg
AM-Pharma B.V., CEO
Erik has over twenty years’ experience in the pharmaceutical and biotechnology industries. Previously, as a Senior Executive at Organon he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis, and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, most recently the $600M alliance with Pfizer and raised more than €200M in equity and debt financing for biotechnology companies from seed through IPO. Erik is board member of Lava Therapeutics, Heatmatrix, Lead Pharma, Step Pharma and the Dutch biotechnology organization. Erik has an MSc in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK) both with distinction.
Juliane Bernholz, PHD
AM-Pharma B.V., Chief Operating Officer